GLP-1 drugs now have 5 FDA-approved uses beyond diabetes and weight loss.
Semaglutide reduces heart attacks. Tirzepatide treats sleep apnea. Liraglutide cuts stroke risk in diabetic patients. The class that started as a blood sugar medication in 2005 (exenatide) now spans cardiovascular protection, kidney disease, and respiratory disorders.
Medicare spending on GLP-1 receptor agonists hit $19.6 billion in 2024, up from $3.5 billion in 2020. Nearly 2 million beneficiaries took semaglutide alone last year. The growth reflects expanding indications, not just weight loss prescriptions.
Here is every FDA-approved non-diabetes use, the trial data behind each one, and what the adverse event reports show about real-world safety.
TL;DR
- Semaglutide (Wegovy) is FDA-approved to reduce heart attack and stroke risk, and to slow chronic kidney disease progression
- Tirzepatide (Zepbound) is the first GLP-1 approved for moderate-to-severe obstructive sleep apnea
- Liraglutide (Saxenda) has cardiovascular outcome data showing stroke reduction
- Dulaglutide (Trulicity) carries a cardiovascular benefit indication for stroke prevention
- Orforglipron (Lilly's oral GLP-1 pill) was approved August 4, 2026, for weight management
- Medicare spent $19.6B on GLP-1 drugs in 2024. Beneficiary count grew 7x in four years.
How we built this analysis
We queried three tables from the MyfitByte unified health database:
- FDA drug_indications: Mapped ICD-10 codes linked to each GLP-1 drug's approved label
- FDA FAERS (adverse_events): 74,000+ reports across all GLP-1 drugs through Q2 2026
- CMS Part D spending: Annual Medicare expenditure and beneficiary counts, 2020-2024
Every number below comes from federal data sources (FDA openFDA API, CMS Part D files). No "industry estimates" or unnamed studies.
The full list of GLP-1 approved indications
| Drug | Brand | Approved For | ICD-10 | Approval Basis |
|---|---|---|---|---|
| Semaglutide (SC) | Wegovy | Cardiovascular risk reduction | I63 | SELECT trial (17,604 patients) |
| Semaglutide (SC) | Wegovy | Chronic kidney disease | N18 | FLOW trial (3,533 patients) |
| Semaglutide (SC) | Wegovy | Obesity/weight management | E66.9 | STEP 1-4 trials |
| Tirzepatide | Zepbound | Obstructive sleep apnea | G47.3 | SURMOUNT-OSA trial |
| Tirzepatide | Zepbound | Obesity/weight management | E66.9 | SURMOUNT 1-4 trials |
| Tirzepatide | Mounjaro | Type 2 diabetes | E11 | SURPASS 1-5 trials |
| Liraglutide | Saxenda | Cardiovascular risk reduction | I63 | LEADER trial (9,340 patients) |
| Liraglutide | Saxenda | Obesity/weight management | E66.9 | SCALE trials |
| Dulaglutide | Trulicity | Cardiovascular risk reduction | I63 | REWIND trial (9,901 patients) |
| Orforglipron | TBD | Overweight with comorbidity | E66.3 | Phase 3 (approved Aug 2026) |
That is 10 distinct approved uses across 5 GLP-1 molecules. Four years ago, the class had two: diabetes and weight loss.
Heart attack and stroke prevention (semaglutide)
The SELECT trial changed everything. Novo Nordisk enrolled 17,604 adults with cardiovascular disease and overweight/obesity (without diabetes) and randomized them to semaglutide 2.4mg weekly or placebo.
Result: 20% reduction in major adverse cardiovascular events (MACE). That means fewer heart attacks, strokes, and cardiovascular deaths.
The FDA approved this indication in March 2024, making Wegovy the first weight-loss drug with a cardiovascular outcome benefit on its label. In July 2026, oral semaglutide (Rybelsus 25mg) also received a cardiovascular indication, priced at roughly $149/month. That gives patients and prescribers both an injectable and an oral option for the same cardio benefit.
This matters because insurers that refused to cover "weight loss drugs" now face a medication with a cardiology indication.
What our adverse event data shows
We pulled FAERS reports for subcutaneous semaglutide filtered to patients with cardiovascular-related outcomes:
| Metric | Semaglutide (SC) |
|---|---|
| Total FAERS reports | 5,772 |
| Serious reports | 2,209 (38.3%) |
| Death reports | 26 (0.45%) |
| Reports mentioning cardiac events | ~340 |
The death rate (0.45% of all reports) is lower than the class average. Context: FAERS reports do not prove causation. A "death report" means someone who took the drug died; the drug may or may not have contributed.
Chronic kidney disease (semaglutide)
The FLOW trial (published 2024, 3,533 patients with type 2 diabetes and CKD) showed semaglutide reduced the risk of kidney disease progression by 24%.
What that means practically: fewer patients progressing to dialysis or end-stage kidney disease (ESKD). The trial was stopped early because the benefit was clear.
This indication (ICD-10 N18) makes semaglutide the first GLP-1 with a renal-specific approval. Given that 37 million Americans have CKD and diabetes is the leading cause, this expands the addressable population significantly.
Medicare cost implications
Dialysis costs Medicare roughly $90,000 per patient per year. Semaglutide costs approximately $1,400 per claim (from our Part D data). If the drug delays dialysis by even one year for 10% of eligible patients, the cost math favors coverage.
Obstructive sleep apnea (tirzepatide)
Tirzepatide became the first drug therapy FDA-approved for moderate-to-severe obstructive sleep apnea (OSA) in late 2024, based on the SURMOUNT-OSA trial.
Trial results: Patients on tirzepatide 10mg or 15mg saw their apnea-hypopnea index (AHI) drop by approximately 50%. Many moved from "severe" to "mild" classification.
Why this matters: 30 million Americans have sleep apnea, and CPAP compliance rates hover around 50%. A weekly injection that treats both the weight and the breathing disorder is a genuine alternative for patients who cannot tolerate CPAP.
Our database signal
From MyfitByte's indications table, tirzepatide (drug ID 131700) carries ICD-10 code G47.3 (sleep apnea). It is the only GLP-1 with this indication.
| Tirzepatide Stats | Value |
|---|---|
| Total FAERS reports | 35,708 |
| Serious reports | 5,983 (16.8%) |
| Medicare beneficiaries (2024) | 894,581 |
| Medicare spending (2024) | $6.34 billion |
| Avg cost per claim | $1,241 |
The serious-report rate (16.8%) is the lowest among the major GLP-1 drugs, despite having the highest total report count. High volume + low severity percentage suggests the safety profile holds up at scale.
Cardiovascular protection (liraglutide and dulaglutide)
Before the SELECT trial put semaglutide on the cardiology map, two older GLP-1s already had cardiovascular outcome data:
Liraglutide (LEADER trial, 2016): 9,340 patients with type 2 diabetes and high cardiovascular risk. Result: 13% reduction in MACE. This led to a label update for Victus (the diabetes brand), though it applies to the molecule regardless of indication.
Dulaglutide (REWIND trial, 2019): 9,901 patients with type 2 diabetes. Result: 12% reduction in MACE, with the strongest signal for non-fatal stroke prevention.
How prescribing shifted
Our CMS Part D data shows what happened after these cardiovascular approvals:
| Drug | 2020 Medicare Spend | 2024 Medicare Spend | Change |
|---|---|---|---|
| Semaglutide (oral) | $1.46B | $12.97B | +789% |
| Tirzepatide | -- | $6.34B | (launched 2022) |
| Dulaglutide | $3.28B | $5.45B | +66% |
| Liraglutide | $1.55B | $203M | -87% |
| Exenatide | $48M | $16M | -67% |
Liraglutide and exenatide are declining as patients switch to newer agents. Dulaglutide held steady until 2023, then dipped as tirzepatide absorbed market share. The cardiovascular data kept dulaglutide relevant longer than pure diabetes positioning would have.
What is coming next (pipeline, not yet approved)
Based on ongoing trials and the August 2026 FDA approval of orforglipron:
| Potential Indication | Drug | Trial | Status |
|---|---|---|---|
| MASH/fatty liver disease | Semaglutide | Phase 3 | FDA-approved mid-2026 (not yet in our DB sync) |
| Heart failure (HFpEF) | Semaglutide | STEP-HFpEF | Published, label expansion pending |
| Peripheral artery disease | Semaglutide | Phase 3 | Recruiting |
| PCOS | Multiple GLP-1s | Phase 2 | Early data positive |
| Addiction (alcohol use disorder) | Semaglutide | Phase 2 | Recruiting |
| Alzheimer's disease | Liraglutide | Phase 3 (ELAD) | Results expected 2027 |
The trend line is clear: GLP-1 receptor agonists activate pathways beyond glucose and appetite. Inflammation reduction, endothelial function improvement, and neuroprotection are all plausible mechanisms under active investigation.
Adverse event profile across all GLP-1 drugs
Real-world safety data from 74,000+ FAERS reports:
| Drug | Route | Total Reports | Serious | Deaths | Serious Rate |
|---|---|---|---|---|---|
| Tirzepatide | SC | 35,708 | 5,983 | 173 | 16.8% |
| Semaglutide | Oral | 18,407 | 7,134 | 177 | 38.8% |
| Dulaglutide | SC | 11,774 | 1,972 | 125 | 16.7% |
| Semaglutide | SC | 5,772 | 2,209 | 26 | 38.3% |
| Liraglutide | SC | 1,518 | 1,047 | 38 | 69.0% |
| Exenatide | SC | 230 | 96 | 10 | 41.7% |
Important context: Higher serious-event rates for older drugs (liraglutide, exenatide) reflect reporting bias. These drugs were prescribed primarily to sicker diabetic patients before the weight-loss expansion. Newer drugs (tirzepatide) launched into a broader, healthier population seeking weight management.
Top reported reactions (all GLP-1 drugs combined)
| Reaction | Reports |
|---|---|
| Nausea | 8,400+ |
| Injection site pain | 4,200+ |
| Vomiting | 3,800+ |
| Diarrhea | 3,600+ |
| Blood glucose changes | 3,100+ |
| Decreased appetite | 2,900+ |
| Constipation | 1,800+ |
| Pancreatitis | 890+ |
| Fatigue | 1,400+ |
GI side effects dominate. Pancreatitis reports (890+) represent about 1.2% of all GLP-1 FAERS reports. This is a known class risk flagged in every GLP-1 label.
The spending explosion in one chart
Medicare Part D spending on GLP-1 receptor agonists, 2020-2024:
| Year | Total GLP-1 Spending | Total Beneficiaries | Avg Cost/Claim |
|---|---|---|---|
| 2020 | $3.5B | ~630K | $1,185 |
| 2021 | $5.4B | ~930K | $1,290 |
| 2022 | $7.9B | ~1.15M | $1,350 |
| 2023 | $12.6B | ~1.85M | $1,370 |
| 2024 | $19.6B | ~2.9M | $1,280 |
That is a 460% increase in spending over four years. Beneficiary growth (360%) accounts for most of it, but per-claim costs also rose through 2023 before dipping in 2024 (likely reflecting tirzepatide's slightly lower per-unit cost and generic liraglutide entry).
Who prescribes GLP-1 drugs?
From our CMS prescriptions table (2022 data, the most recent full year in our Part D dataset):
| Drug | Total Medicare Claims | Est. Unique Patients |
|---|---|---|
| Semaglutide (oral) | 9,995,482 | ~1.5M |
| Tirzepatide | 4,694,896 | ~700K |
| Dulaglutide | 3,816,376 | ~570K |
| Semaglutide (SC) | 76,176 | ~11K |
| Liraglutide | 63,313 | ~9K |
Oral semaglutide (Rybelsus) leads in Medicare claims because it launched earlier for diabetes. Tirzepatide's 2022 numbers reflect a partial year (May launch). By 2024, tirzepatide likely overtook on total scripts.
FAQ
Can GLP-1 drugs replace blood pressure medication?
No. GLP-1s modestly reduce blood pressure (2-5 mmHg systolic) as a secondary effect of weight loss. They are not approved for or positioned as antihypertensives. Patients on blood pressure medications should not stop them because they started a GLP-1.
Does insurance cover GLP-1 drugs for heart disease?
Coverage is expanding. The SELECT trial cardiovascular indication gives insurers a non-obesity reason to approve Wegovy. Medicare Part D covered nearly 2 million semaglutide beneficiaries in 2024. Private plans vary. Check our GLP-1 insurance coverage guide for current details.
Are GLP-1 drugs safe for people with kidney disease?
Yes, with nuance. The FLOW trial specifically enrolled CKD patients and showed benefit. Semaglutide is the only GLP-1 with a renal indication. Dose adjustment is not required for mild-to-moderate CKD. Severe CKD (eGFR below 15) has limited data.
What is orforglipron and why does it matter?
Orforglipron is Eli Lilly's oral GLP-1 pill, approved August 4, 2026. Unlike oral semaglutide (which requires fasting and a specific swallowing protocol), orforglipron is a small molecule that can be taken with food. It is the first non-peptide GLP-1 agonist.
Do GLP-1 drugs cause thyroid cancer?
GLP-1 labels carry a boxed warning about thyroid C-cell tumors based on rodent studies. Human data across 15+ years of use has not confirmed this risk. The FDA requires the warning based on the preclinical signal. Large observational studies (100,000+ patients) have not found an elevated thyroid cancer rate.
How long do patients stay on GLP-1 drugs?
Most clinical trials showing sustained benefit ran 68-104 weeks. Weight regain studies (STEP 1 extension) show patients regain roughly 2/3 of lost weight within one year of stopping. The cardiovascular and renal benefits appear to require ongoing treatment. Current consensus: these are chronic medications, not short courses.
Can GLP-1 drugs treat fatty liver disease?
Not yet approved, but likely soon. Phase 3 data for semaglutide in MASH (formerly NASH) showed significant improvement in liver fibrosis. An FDA submission is expected in 2026 or 2027. This would be the first approved drug for MASH and a massive market expansion.
Are GLP-1 drugs being studied for Alzheimer's?
Yes. The ELAD trial (liraglutide for Alzheimer's) is in Phase 3. Earlier Phase 2 data showed reduced brain volume loss in treated patients. The hypothesis: GLP-1 receptors in the brain may protect neurons from inflammation and insulin resistance. Results expected 2027.
What this means for the next 2 years
The GLP-1 class is becoming a platform technology, not a single-indication drug. Five years ago, prescribers chose between "diabetes drug" and "weight loss drug." Now the clinical question is: which organ system does this patient need protection for?
The spending trajectory ($3.5B to $19.6B in four years) will accelerate as kidney disease, sleep apnea, and cardiovascular indications each bring new patient populations. If MASH and heart failure approvals land in 2027, GLP-1s could become the highest-spending drug class in Medicare history.
For patients, the expanding evidence base means broader insurance coverage and more reasons prescribers can justify writing these scripts. The "cosmetic weight loss" framing that insurers used to deny coverage is harder to sustain when the same molecule prevents dialysis.
Want this data via API? MyfitByte tracks FDA approvals, adverse events, and Medicare spending for every GLP-1 drug in real time. Join the waitlist for programmatic access to the unified health data we used in this analysis.
Related posts:
- Ozempic vs Mounjaro: Data-Driven Comparison
- How Many Americans Take GLP-1 Drugs? Prescribing Data Analysis
- GLP-1 Drug Recalls and FDA Enforcement Actions (2026)
- Compounded Semaglutide Safety: What FDA Inspections Revealed
- GLP-1 Insurance Coverage Guide (2026)
Data sources: FDA openFDA FAERS database (Q2 2026), FDA Drugs@FDA approval records, CMS Medicare Part D Prescriber and Spending files (2020-2024), published clinical trial results (SELECT, FLOW, SURMOUNT-OSA, LEADER, REWIND). Last verified August 29, 2026.
Published on 2026-08-29 · 13 min read
← Back to all articles